Lung cancer is the major cancer killer in the Western world, with the small cell lung cancer (SCLC) representing around 15-20% of all lung cancers. Extensive disease small cell lung cancer (ED SCLC) is found in approximately two-thirds of all cases, composed of both metastatic (M1) and non-metastatic (but presumably with tumor burden too large for locoregional-only approach) variant. Standard treatment options involve chemotherapy (CHT) over the past several decades. Radiation therapy (RT) had mostly been used in palliation of locoregional and/or metastatic disease. In contrast to its established role in treating metastatic disease, thoracic RT (TRT) had never been established as important part of the treatment aspects in this setting. In the past two decades, thoracic oncologists have witnessed wide introduction of modern RT and CHT aspects in ED SCLC, which led to more frequent use of RT and rise in the number of clinical studies. Since the pivotal study of Jeremic et al., who were the first to show
RATIONALE: Sorafenib may stop the growth of small cell lung cancer by blocking blood flow to the tumor and by blocking some of the enzymes needed for ce
BM is a well-known negative prognostic factor in SCLC and NSCLC patients, and a previous retrospective analysis of SCLC patients showed significantly shorter OS of patients with BM than among patients without BM [4.13 vs. 6.17 months, P=0.015 (11)]. In NSCLC patient cohorts, the incidence of SREs is also a known negative prognostic factor, with one year survival rates of 5.1 and 12.1% in a retrospective cohort study of lung cancer patients with and without SREs, respectively (12). However, this study showed no significant differences in OS between ES-SCLC patients with BM and metastasis in the brain, liver, adrenal glands and pleural cavities. Other studies suggest that liver metastases are the worst prognostic factor in patients with ES-SCLC (13,14), and that BM and brain metastases are similarly negative survival indicators. Specifically, one-year survival of SCLC patients with liver, brain and BM was 14.5, 25.1 and 23.9%, respectively (13), warranting consideration of BM as an important ...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
We conducted a trial of adaptive radiotherapy (RT) for limited stage small cell lung cancer (LS-SCLC) to quantify the dosimetric advantages, toxicity, survival and failure patterns associated with this technique.
OBJECTIVES: I. Determine the dose, safety, and antitumor response rate of lepirudin in patients with recurrent or extensive stage small cell lung cancer previously treated with chemotherapy.. OUTLINE: This is a dose escalation (in individual patients) study. Patients receive dose escalated lepirudin subcutaneously once or twice a day for 3-4 days. Dose escalation continues in each patient until aPTT prolongation occurs or the maximum dose level is reached. The patient then continues treatment on the maximum tolerated dose. Treatment continues in the absence of disease progression or unacceptable toxicity.. PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study within 18-24 months. ...
Video created by University of Michigan for the course Thoracic Oncology. After reviewing this unit, the learner will understand basic principles regarding: 2000+ courses from schools like Stanford and Yale - no application required. Build ...
Abstract: PURPOSE: A retrospective study was performed to evaluate the efficiency and feasibility of twice daily radiation therapy plus concurrent chemotherapy for limited-stage small cell lung cancer in terms of treatment response, survival, patterns of failure, and acute toxicities. MATERIALS AND METHODS: Between February 1993 and October 2002, 76 patients of histologically proven limited-stage small cell lung cancer (LS-SCLC) were treated with twice daily radiation therapy and concurrent chemotherapy. Male was in 84% (64/76), and median age was 57 years (range, 32~75 years). Thoracic radiation therapy consisted of 120 or 150 cGy per fraction, twice a day at least 6 hours apart, 5 days a week. Median total dose was 50.4 Gy (range, 45~51 Gy). Concurrent chemotherapy consisted of CAV (cytoxan 1000 mg/m2, adriamycin 40 mg/m2, vincristine 1 mg/m2) alternating with PE (cisplatin 60 mg/m2, etoposide 100 mg/m2) or PE alone, every 3 weeks. The median cycle of chemotherapy was six (range, 1~9 cycle). ...
The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian Multicenter Random
TY - JOUR. T1 - Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer. AU - Lohinai, Zoltan. AU - Bonanno, Laura. AU - Aksarin, Aleksei. AU - Pavan, Alberto. AU - Megyesfalvi, Zsolt. AU - Santa, Balazs. AU - Hollosi, Virag. AU - Hegedus, Balazs. AU - Moldvay, Judit. AU - Conte, PierFranco. AU - Ter-Ovanesov, Mikhail. AU - Bilan, Evgeniy. AU - Dome, Balazs. AU - Weiss, Glen J. PY - 2019/7/29. Y1 - 2019/7/29. N2 - Background: For selected early stage small cell lung cancer (SCLC), curative intent surgery is often performed. Previous studies, predominantly from East Asia, reported that high neutrophil to lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) correlate with poor prognosis in several types of tumors including SCLC. Our aim was to investigate the prognostic value of NLR and PLR in Caucasian patients with resected SCLC, as potential tool to select patients for multimodal treatment including surgery.Methods: Consecutive patients evaluated at three ...
The majority of small cell lung cancer(SCLC)(50-100%) express somatostatin receptors(type 1-5) with some small cell lung cancer express more than one su
Context: Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in diverse human cancers and plays a critical role in tumor cell survival, proliferation, migration, invasion, angiogenesis, and inhibition of apoptosis. The phosphorylated active form of STAT3 (pSTAT3) mediates its effects via nuclear transcriptional activity. However, it was recently observed that the nonphosphorylated, cytoplasmic, inactive form of STAT3 is involved in cell motility and consequently tumor invasion. It appears that, although STAT3 is not absolutely required for tumor formation, tumors that develop in the presence of STAT3 become dependent on its expression for their survival, making it a potential therapeutic target.. Objective: To investigate the possible utility of STAT3 as a future therapeutic target in nonâ€"small cell lung carcinoma (NSCLC) and malignant mesothelioma (MM).. Design: Immunohistochemical expression of MIB-1, STAT3, and pSTAT3 was assessed in 303 NSCLC and 44 MM ...
Researchers at Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (Western), in collaboration with international colleagues, found that statins could be an effective therapeutic against metastatic small cell lung cancer. The study of 876 late-stage SCLC patients, published today in the scientific journal PLOS ONE, showed that statins, a class of drugs primarily used to lower cholesterol in patients at risk for heart disease, appeared to provide an increase in overall survival.
MicroRNA Expression and Clinical Outcome of Small Cell Lung Cancer. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Study Small Cell Lung Cancer using smart web & mobile flashcards created by top students, teachers, and professors. Prep for a quiz or learn for fun!
I am 15 and my boyfriend just told me he has this cancer and is at stage 4.... Im not really sure what any of this means and hes out of state so I cant be at the hospital with him to communicate with him at all. Hes also deaf so I can not call him and talk to him about it so Id really appreciate if someone can just give me a little information on this. Thanks for your time and answers.. ...
Critique: Brain imaging not required prior to randomization or with followup. Therefore, patients may have had subclinical brain mets (that would have been seen on MRI) in the radiation group and extensive stage group. Applicability of this study to MRI negative extensive stage patients is difficult to interpret. NCCN has PCI with extensive stage with response to chemotherapy and good PS as category 1 ...
Single-agent atezolizumab (formerly MPDL3280A) had excellent clinical activity in both chemotherapy-naïve and previously treated patients with metastatic nonâ€
REDWOOD CITY, Calif., Aug. 30, 2016-- OncoMed Pharmaceuticals Inc., a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the completion of patient enrollment in the Phase 2
PHSS January Regulatory Update 2016 On this months PHSS Regulatory Update reported issues have come from the EU and USA regulatory authorities.. The topics covered in this edition of the "Update" include:. Europe. ...
mimoOn LTE Small Cell Software Available for Broadcoms Dual-Mode Small Cell SoC Family: mimoOn GmbH, a leading LTE software vendor for Small Cells and terminals, announced the availability of its LTE protocol stack (mi!SmallCellSTACK™) for Broadcoms dual-mode small cell family of SoCs. Small Cell product developers now can turn to a robust, high-performing product that is designed and supported by mimoOns team of engineers, who have experience in designing …
My dad was recently dx. w/ small cell ca of the lung, and I realized that ER and OR nursing has not prepared me for the questions that my family expects me to be able to answer. What I need from
Steve Shipley, General Manager APAC, presented at Small Cells Asia 2012 in Taipei. Smart cells are a combination of small cell and compute platform pioneered b…
It may be early days for outdoor small cell development, but the demand has been there for quite some time. And, in the future, the demand will only continue to grow as beefier public and business devices become accustomed to the additional support that they bring. We can expect small cells to become a more ubiquitous part of the device ecosystem ...
Numerous typical whorl formations (A) and small cells with a high nuclear/cytoplasmic ratio (B) were observed in the tumor. Spontaneous necrosis was occasionall
The company is sampling its third-generation low-power small cell SoCs, which officials say will improve users wireless experiences.
Small cells have taken far longer than many have expected to take hold in the market, but now as the industry is maturing whats needed for several different deployment scenarios.
TY - JOUR. T1 - Delayed leuko-encephalopathy in survivors with small cell lung cancer. AU - So, N. K.. AU - ONeill, B. P.. AU - Frytak, S.. AU - Eagan, R. T.. AU - Earnest, F.. AU - Lee, R. E.. PY - 1987/7. Y1 - 1987/7. N2 - Six patients with small cell lung cancer developed a. slowly progressive neurologic syndrome characterized by apathy, abulia, memory loss, gait ataxia, and corticospinal tract signs 26 to 50 months (mean, 35.2 months) after prophylactic cranial irradiation and systemic chemotherapy. In each case this was accompanied by CT and/or MRI evidence of changes in the peri-ventricular white matter. These patients are long-term survivors (41 to 69 months) and do not have CNS metastases.. AB - Six patients with small cell lung cancer developed a. slowly progressive neurologic syndrome characterized by apathy, abulia, memory loss, gait ataxia, and corticospinal tract signs 26 to 50 months (mean, 35.2 months) after prophylactic cranial irradiation and systemic chemotherapy. In each case ...
TY - JOUR. T1 - Report From the International Atomic Energy Agency (IAEA) Consultants Meeting on Elective Nodal Irradiation in Lung Cancer. T2 - Non-Small-Cell Lung Cancer (NSCLC). AU - Belderbos, José S.A.. AU - Kepka, Lucyna. AU - Kong, Feng Ming. AU - Martel, Mary K.. AU - Videtic, Gregory M.M.. AU - Jeremic, Branislav. PY - 2008/10/1. Y1 - 2008/10/1. N2 - Lymphatic spread is an important pathway of progression in non-small-cell lung cancer (NSCLC), along with local spread and distant metastasis. The probability of lymph node (LN) involvement is dependent on the site of the primary tumor, stage, and histology. Elective nodal irradiation (ENI) is the irradiation of clinical and radiological uninvolved LN to account for microscopic tumor invasion in these LNs because we have not been able to determine the extent of LN spread accurately. The clinical value of ENI is uncertain. The impact of ENI is dependent on many (staging-, treatment-, and patient-related) factors. The purpose of this report ...
Small cell lung cancer accounts for approximately 15% of all lung cancers and has high metastatic potential and poor clinical outcomes. While untreated small cell lung cancers are usually highly sensitive to cytotoxic chemotherapy-with response rates of between 50% and 70%-patients often relapse, necessitating novel treatments strategies.. A phase I/II study of a combination of the poly ADP ribose polymerase (PARP) inhibitor olaparib and the chemotherapy agent temozolomide in patients with relapsed small cell lung cancer has found that the therapy had substantial clinical activity in these patients. In addition, a clinical study in animal models to identify molecular signatures that may be predictive of response to the therapy has found that a specific molecular signature of four inflammatory response genes could distinguish sensitive from resistant models in both the discovery and validation cohorts, and may provide a molecular signature of those tumors most likely to respond to ...
Small cell lung cancer information with its causes along with various signs and symptoms. The fluid in the lungs may be an indication of this cancer but this may not be a sure sign of the disease. Detailed description of small cell lung cancer different treatment methods also given.
TY - JOUR. T1 - Limited value of CT brain scans in the staging of small cell lung cancer. AU - Johnson, D. H.. AU - Windham, W. W.. AU - Allen, J. H.. AU - Greco, F. A.. PY - 1982/1/1. Y1 - 1982/1/1. N2 - Computed tomography of the brain was performed as part of the initial staging evaluation of 84 patients with small cell lung cancer. Brain scans indicative of metastatic disease were obtained in 12 (14%) patients, two of whom had no neurologic signs or symptoms. One of these had no other extrathoracic disease. Brain scans without evidence of metastatic diseases were obtained in 72 patients, 58 (80.5%) of whom had no signs or symptoms suggestive of metastatic intracranial disease. In the 14 patients with neurologic symptoms but negative computed tomographic scans, other explanations than brain metastases were found. It was concluded that head scanning is a sensitive and accurate method of detecting central nervous system metastases in patients with small cell lung cancer. However, head computed ...
Management of limited small cell lung cancer(SCLC). small cell lung cancer is very responsive to chemotherapy and radiotherapy. Most of the times it is disseminated. Surgery should only be done when chemotherapy has failed. Platinum compounds and etoposide combined with thoracic radiation is used. Prognosis and survival in small cell lung cancer; mosts of the times the patients present with a disseminated disease. If not treated, patients can survive for up to four months. when treated early, patients can live up to two years without the disease. About 5-10% of patients treated live up to five years.. Management of advanced small cell lung cancer(SCLC). The first line drugs in treatment of advanced small cell lung cancer is a combination of carboplastin or cisplatin combined with etoposide. Patients with small cell lung cancer have poor survival rates of ten months to two years in about 10% of the patients. ...
... is also called oat cell cancer. About 10%-15% of lung cancers are small cell lung cancers. This type of lung cancer tends to spread quickly.
Each year, 13 percent of all newly diagnosed lung cancer patients are diagnosed with small-cell lung cancer (SCLC). Approximately 39 percent of patients with SCLC are diagnosed with limited-stage disease, meaning the cancer ...
TY - CHAP. T1 - Bombesin stimulates growth of human small cell lung carcinoma in vivo. AU - Alexander, R. W.. AU - Upp, J. R.. AU - Poston, G. J.. AU - Gupta, V.. AU - Townsend, Courtney. AU - Thompson, J. C.. PY - 1987. Y1 - 1987. UR - http://www.scopus.com/inward/record.url?scp=0023610349&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0023610349&partnerID=8YFLogxK. M3 - Chapter. AN - SCOPUS:0023610349. VL - 38. SP - 450. EP - 452. BT - Surgical Forum. ER - ...
To analyze the feasibility of omitting clinical target volume (CTV) for limited small cell lung cancer treated with chemotherapy and intensity modulated radiotherapy. 89 patients were treated from January 1, 2008 to August 31, 2011, 54 cases were irradiated with target volume without CTV, and 35 cases were irradiated with CTV. Both arms were irradiated post chemotherapy tumor extent and omitted elective nodal irradiation; dose prescription was 95% PTV56-63 Gy/28-35 F/5.6-7 weeks. In the arm without CTV and arm with CTV, the local relapse rates were 16.7% and 17.1% (p = 0.586) respectively. In the arm without CTV, of the 9 patients with local relapse, 6 recurred in-field, 2 recurred in margin, 1 recurred out of field. In the arm with CTV, of the 6 patients with local relapse, 4 recurred in-field, 1 recurred in margin, 1 recurred out of field. The distant metastases rates were 42.6% and 51.4% (p = 0.274) respectively. Grade 3-4 hematological toxicity and radiation esophagitis had no statistically
Small cell lung cancer treatment options include surgery, chemotherapy and radiation therapy, laser therapy, targeted therapy, and supportive care. Learn more about treatments for newly diagnosed and recurrent small cell lung cancer in this expert-reviewed summary.
The combination of chemo- and radiotherapy has resulted in prolonged survival and potential cures in patients with some neoplastic diseases. Small cell lung cancer (SCLC) is one of those neoplasms in...
A specific, acquired chromosomal abnormality (deletion 3p) has been found in at least one chromosome 3 in 100 percent of the metaphases in 12 of 12 cell lines cultured from human small-cell lung cancer tissue and in 2-day tumor culture specimens from three patients. Analysis of the shortest region of overlap shows the deletion to be 3p(14-23). This specific change was not seen in five of five lung cancer cell lines other than small-cell lung cancer or in two lymphoblastoid lines cultured from cells of small-cell lung cancer patients whose tumors had the 3p deletion. ...
Purpose: Neurocognitive impairment (NI) in patients with small cell lung cancer (SCLC) after whole brain radiation treatment (WBRT) is a significant cause of morbidity. Hippocampal avoidance (HA) during WBRT may mitigate or prevent NI in such patients. However, this has not been tested in SCLC patients. The estimated risk of metastases in the HA region (HM) in patients with SCLC at diagnosis or after WBRT is unknown. Our study aimed to determine the risk of HM in patients with SCLC and to assess correlated clinical factors. Methods and Materials: Patients with SCLC who experienced brain metastases (BM) at presentation (de novo) or after WBRT treated at the Saskatoon Cancer Centre between 2005 and 2012 were studied. Relevant neuroimaging was independently reviewed by a neuroradiologist. HM was defined as metastases within 5 mm of the hippocampus. Logistic regression analysis was performed to assess correlation between various clinical variables and HM. Results: Seventy eligible patients were ...
Background Small cell lung cancer (SCLC) is a common lung cancer which presents with extensive stage disease at time of diagnosis in two-thirds of patients. For treatment of advanced disease, traditional platinum doublet chemotherapy induces response rates up to 80% but with few durable responses. CPI-613 is a novel anti-cancer agent that selectively inhibits the altered form of mitochondrial energy metabolism in tumor cells. Methods We evaluated CPI-613 with a single-arm, open-label phase II study in patients with relapsed or refractory SCLC. CPI-613 was given at a dose of 3,000 mg/m2 on days 1 and 4 of weeks 1-3 of 4 week cycle. The primary outcome was response rate as assessed by CT imaging using RECIST v1.1 criteria. Secondary outcomes were progression-free survival (PFS), overall survival (OS), and toxicity. Twelve patients were accrued (median age 57yo) who had previously received between 1 and 4 lines of chemotherapy (median 1) for SCLC with a treatment-free interval of less than 60 days in 9
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
The small cell lung cancer is characterized as a rapidly proliferating systemic neoplasm, where the basic treatment modality is the chemotherapy . Even in the surgically treated cases the platina based chemotherapy combination is obligatory before and after the surgical resection, combined with preventiv cranial irradiation to minimize the risk of the cranial metastases. The platina based chemo-radiotherapy is the gold standard in the locally advanced cases. Palliativ local irradiation could be useful for pain relief or decompression in the metastatic cases. Prophylactic cranial irradiation strongly recommended in any cases. There are no newly developed drugs for the treatment of SCLC, however it is a chemosensitive carcinoma. Topotecan could be effective in second or third line therapy , especially in brain metastasis.. ...
The identification of genes undergoing genetic or epigenetic alterations and contributing to the development of cancer is critical to our understanding of the molecular mechanisms of carcinogenesis. A new approach in identifying alterations of genes that might be relevant to the process of tumor development was used in this study by examining the gene expression profile in human lung cancer cells
The immunotherapy agent Keytruda (pembrolizumab) had an overall response rate (ORR) of 33 percent in a recent trial including patients with extensive-stage small cell lung cancer (SCLC). Findings of the phase 1b KEYNOTE-028 trial were published in the |em|Journal of Clinical Oncology.|/em|
This study will be investigating nintedanib [BIBF-1120; Boehringer Ingelheim] in small cell lung cancer patients who have previously benefited from first line
Small cell lung cancer (SCLC) is a highly lethal malignancy with the 5-year survival rate of less than 7%. Chemotherapy-resistance is a major challenge for SCLC treatment in clinic. In the study, we...
Most of the presenting symptoms of small cell lung cancer are non-specific in nature. However, many of them are common symptoms such as persistent cough, shortness of breath, coughing up blood, pain in the chest, or unresolved pneumonia. If the cancer spreads to distant areas, more symptoms may emerge such as difficulties in swallowing, hoarse voice, and swelling of the face or hands.
Summary GlobalDatas clinical trial report, Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 provides an overview of Small-Cell Lung Cancer